论文部分内容阅读
为了评估口服卡介苗（BCG）预防浅表性膀胱肿瘤复发的临床价值，对71例浅表性膀胱肿瘤进行长期随访，并行外周血NK细胞活性测定。结果表明71例中有50例（70．4％）有完全反应（CR），21例（29．6％）肿瘤复发，治疗3周和6周后，NK细胞活性明显升高（P＜0．01）。认为NK细胞活性升高与口服BCG治疗反应有关；口服BCG可以提高机体免疫力，对预防浅表性膀胱肿瘤复发有较大价值。
In order to assess the clinical value of oral BCG in preventing the recurrence of superficial bladder tumor, 71 cases of superficial bladder tumor were followed up for a long time, and NK cell activity in peripheral blood was measured. The results showed that in 71 cases, 50 cases (70.4%) had complete response (CR) and 21 cases (29.6%) had tumor recurrence. After 3 weeks and 6 weeks of treatment, NK cell activity was significantly increased (P <0 .01). It is considered that the increase of NK cell activity is related to the response of oral BCG treatment. Oral administration of BCG can improve the immunity of the body and is of great value in preventing the recurrence of superficial bladder tumor.